Cyclo Therapeutics, Inc. (CYTH)
USD 0.72
(0.0%)
USD 0.72
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.03 Million USD | 0.0% |
| 2022 | - USD | -100.0% |
| 2021 | 170.99 Thousand USD | -12.06% |
| 2020 | 194.44 Thousand USD | 270.29% |
| 2019 | 52.51 Thousand USD | 0.0% |
| 2018 | - USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | -100.0% |
| 2015 | 754.03 Thousand USD | -5.09% |
| 2014 | 794.49 Thousand USD | -6.72% |
| 2013 | 851.77 Thousand USD | -13.62% |
| 2012 | 986.06 Thousand USD | 17.84% |
| 2011 | 836.8 Thousand USD | 90.63% |
| 2010 | 438.97 Thousand USD | 0.0% |
| 2009 | - USD | 0.0% |
| 2008 | - USD | -100.0% |
| 2007 | 161.4 Thousand USD | 8.92% |
| 2006 | 148.18 Thousand USD | -6.45% |
| 2005 | 158.39 Thousand USD | -26.2% |
| 2004 | 214.63 Thousand USD | 12.41% |
| 2003 | 190.94 Thousand USD | 18.31% |
| 2002 | 161.38 Thousand USD | -14.71% |
| 2001 | 189.21 Thousand USD | -15.31% |
| 2000 | 223.43 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 2.99 Million USD | 350.62% |
| 2024 Q1 | 665.06 Thousand USD | -35.63% |
| 2023 Q1 | 53.49 Thousand USD | 0.0% |
| 2023 FY | 1.03 Million USD | 0.0% |
| 2023 Q2 | 49.4 Thousand USD | -7.65% |
| 2023 Q4 | 1.03 Million USD | 2184.04% |
| 2023 Q3 | 45.23 Thousand USD | -8.45% |
| 2022 Q3 | 4978.00 USD | -49.23% |
| 2022 Q4 | - USD | -100.0% |
| 2022 Q1 | 14.56 Thousand USD | -91.48% |
| 2022 FY | - USD | -100.0% |
| 2022 Q2 | 9805.00 USD | -32.66% |
| 2021 Q1 | 191.4 Thousand USD | -1.56% |
| 2021 Q3 | 175.6 Thousand USD | -6.06% |
| 2021 Q4 | 170.99 Thousand USD | -2.63% |
| 2021 FY | 170.99 Thousand USD | -12.06% |
| 2021 Q2 | 186.93 Thousand USD | -2.34% |
| 2020 Q1 | 48.48 Thousand USD | -7.67% |
| 2020 FY | 194.44 Thousand USD | 270.29% |
| 2020 Q4 | 194.44 Thousand USD | -2.18% |
| 2020 Q3 | 198.77 Thousand USD | -2.05% |
| 2020 Q2 | 202.94 Thousand USD | 318.56% |
| 2019 FY | 52.51 Thousand USD | 0.0% |
| 2019 Q1 | 64.23 Thousand USD | 0.0% |
| 2019 Q2 | 60.38 Thousand USD | -5.99% |
| 2019 Q3 | 56.47 Thousand USD | -6.47% |
| 2019 Q4 | 52.51 Thousand USD | -7.02% |
| 2018 Q1 | - USD | 0.0% |
| 2018 FY | - USD | 0.0% |
| 2018 Q4 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q2 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 Q4 | - USD | -100.0% |
| 2016 Q1 | 708.57 Thousand USD | -6.03% |
| 2016 Q2 | 688.73 Thousand USD | -2.8% |
| 2016 Q3 | 608.23 Thousand USD | -11.69% |
| 2016 FY | - USD | -100.0% |
| 2015 Q4 | 754.03 Thousand USD | 0.54% |
| 2015 Q1 | 779.7 Thousand USD | -1.86% |
| 2015 Q2 | 764.93 Thousand USD | -1.89% |
| 2015 FY | 754.03 Thousand USD | -5.09% |
| 2015 Q3 | 750.01 Thousand USD | -1.95% |
| 2014 Q2 | 823.37 Thousand USD | -4.06% |
| 2014 FY | 794.49 Thousand USD | -6.72% |
| 2014 Q3 | 809.05 Thousand USD | -1.74% |
| 2014 Q4 | 794.49 Thousand USD | -1.8% |
| 2014 Q1 | 858.18 Thousand USD | 0.75% |
| 2013 Q2 | 907.7 Thousand USD | -4.26% |
| 2013 Q3 | 904.17 Thousand USD | -0.39% |
| 2013 Q4 | 851.77 Thousand USD | -5.8% |
| 2013 FY | 851.77 Thousand USD | -13.62% |
| 2013 Q1 | 948.06 Thousand USD | -3.85% |
| 2012 Q4 | 986.06 Thousand USD | 13.08% |
| 2012 Q1 | 896.44 Thousand USD | 7.13% |
| 2012 Q2 | 884.44 Thousand USD | -1.34% |
| 2012 FY | 986.06 Thousand USD | 17.84% |
| 2012 Q3 | 871.98 Thousand USD | -1.41% |
| 2011 Q4 | 836.8 Thousand USD | 3.47% |
| 2011 Q3 | 808.77 Thousand USD | 7.19% |
| 2011 Q1 | 760.87 Thousand USD | 73.33% |
| 2011 Q2 | 754.49 Thousand USD | -0.84% |
| 2011 FY | 836.8 Thousand USD | 90.63% |
| 2010 FY | 438.97 Thousand USD | 0.0% |
| 2010 Q2 | - USD | 0.0% |
| 2010 Q4 | 438.97 Thousand USD | -0.23% |
| 2010 Q3 | 440 Thousand USD | 0.0% |
| 2010 Q1 | - USD | 0.0% |
| 2009 Q2 | - USD | 0.0% |
| 2009 Q4 | - USD | 0.0% |
| 2009 FY | - USD | 0.0% |
| 2009 Q1 | - USD | 0.0% |
| 2009 Q3 | - USD | 0.0% |
| 2008 FY | - USD | -100.0% |
| 2008 Q4 | - USD | 0.0% |
| 2008 Q3 | - USD | 0.0% |
| 2008 Q2 | - USD | -100.0% |
| 2008 Q1 | 25.85 Thousand USD | -83.98% |
| 2007 Q2 | 145.02 Thousand USD | -1.38% |
| 2007 Q1 | 147.05 Thousand USD | -0.76% |
| 2007 Q4 | 161.4 Thousand USD | 12.87% |
| 2007 FY | 161.4 Thousand USD | 8.92% |
| 2007 Q3 | 142.99 Thousand USD | -1.4% |
| 2006 Q4 | 148.18 Thousand USD | -1.12% |
| 2006 FY | 148.18 Thousand USD | -6.45% |
| 2006 Q3 | 149.85 Thousand USD | -1.08% |
| 2006 Q2 | 151.5 Thousand USD | -1.05% |
| 2006 Q1 | 153.11 Thousand USD | -3.33% |
| 2005 FY | 158.39 Thousand USD | -26.2% |
| 2005 Q4 | 158.39 Thousand USD | -5.78% |
| 2005 Q1 | 179.49 Thousand USD | -16.37% |
| 2005 Q2 | 191.19 Thousand USD | 6.52% |
| 2005 Q3 | 168.11 Thousand USD | -12.07% |
| 2004 Q1 | 188.45 Thousand USD | -1.31% |
| 2004 Q3 | 183.67 Thousand USD | -1.21% |
| 2004 Q2 | 185.92 Thousand USD | -1.34% |
| 2004 FY | 214.63 Thousand USD | 12.41% |
| 2004 Q4 | 214.63 Thousand USD | 16.86% |
| 2003 Q4 | 190.94 Thousand USD | -27.97% |
| 2003 FY | 190.94 Thousand USD | 18.31% |
| 2003 Q1 | 158.5 Thousand USD | -1.79% |
| 2003 Q2 | 180.75 Thousand USD | 14.03% |
| 2003 Q3 | 265.09 Thousand USD | 46.67% |
| 2002 Q4 | 161.38 Thousand USD | -0.87% |
| 2002 Q1 | 297.41 Thousand USD | 57.18% |
| 2002 FY | 161.38 Thousand USD | -14.71% |
| 2002 Q2 | 165.56 Thousand USD | -44.33% |
| 2002 Q3 | 162.8 Thousand USD | -1.67% |
| 2001 Q4 | 189.21 Thousand USD | -1.43% |
| 2001 Q3 | 191.95 Thousand USD | -1.53% |
| 2001 FY | 189.21 Thousand USD | -15.31% |
| 2001 Q1 | 214.7 Thousand USD | -3.91% |
| 2001 Q2 | 194.93 Thousand USD | -9.21% |
| 2000 Q4 | 223.43 Thousand USD | -3.2% |
| 2000 Q3 | 230.81 Thousand USD | 0.0% |
| 2000 FY | 223.43 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 540.94 Million USD | 99.809% |
| Theratechnologies Inc. | 58.96 Million USD | 98.248% |
| Safety Shot Inc | 1.54 Million USD | 33.303% |
| Cosmos Health Inc. | 12.42 Million USD | 91.684% |
| Cronos Group Inc. | 2.53 Million USD | 59.325% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 99.856% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | 97.156% |
| Organogenesis Holdings Inc. | 119.35 Million USD | 99.134% |
| Universe Pharmaceuticals INC | 5.48 Million USD | 81.156% |
| ProPhase Labs, Inc. | 21.38 Million USD | 95.168% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -69.92% |
| Dynavax Technologies Corporation | 256.91 Million USD | 99.598% |
| Radius Health, Inc. | 365.31 Million USD | 99.717% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | 60.977% |
| Alvotech | 1.07 Billion USD | 99.904% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -57.079% |
| Alpha Teknova, Inc. | 30.45 Million USD | 96.608% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | 93.901% |
| SCYNEXIS, Inc. | 15.08 Million USD | 93.149% |
| Harrow Health, Inc. | 190.5 Million USD | 99.458% |
| Biofrontera Inc. | 5.39 Million USD | 80.865% |
| DURECT Corporation | 20.74 Million USD | 95.02% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | 97.512% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | 99.672% |
| OptiNose, Inc. | 131.74 Million USD | 99.216% |
| RedHill Biopharma Ltd. | 1.17 Million USD | 11.926% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | 98.955% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | 94.394% |
| SIGA Technologies, Inc. | 1.46 Million USD | 29.432% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | 99.207% |
| Shineco, Inc. | 29.65 Million USD | 96.516% |
| Phibro Animal Health Corporation | 525.45 Million USD | 99.803% |
| Procaps Group S.A. | 285.93 Million USD | 99.639% |
| TherapeuticsMD, Inc. | 8 Million USD | 87.094% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -1627.415% |
| Viatris Inc. | 18.12 Billion USD | 99.994% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -57.079% |
| Rockwell Medical, Inc. | 13.43 Million USD | 92.313% |
| Incannex Healthcare Limited | 373 Thousand USD | -176.975% |
| Aytu BioPharma, Inc. | 15.12 Million USD | 93.171% |
| Tilray Brands, Inc. | 387.31 Million USD | 99.733% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 99.847% |
| PetIQ, Inc. | 468.3 Million USD | 99.779% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 99.759% |
| Journey Medical Corporation | 17.73 Million USD | 94.173% |
| Alimera Sciences, Inc. | 67.39 Million USD | 98.467% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | 87.518% |
| Assertio Holdings, Inc. | 40.91 Million USD | 97.475% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | 5.018% |
| Embecta Corp. | 1.63 Billion USD | 99.937% |
| Procaps Group, S.A. | 285.93 Million USD | 99.639% |
| PainReform Ltd. | 86 Thousand USD | -1101.297% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | 97.08% |
| Hempacco Co., Inc. | 13.72 Million USD | 92.472% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 99.824% |
| Alvotech | 1.07 Billion USD | 99.904% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 99.833% |
| Kamada Ltd. | 8.74 Million USD | 88.192% |
| Indivior PLC | 281.6 Million USD | 99.633% |
| Currenc Group, Inc. | 31.94 Million USD | 96.766% |
| Evoke Pharma, Inc. | 5 Million USD | 79.338% |
| Flora Growth Corp. | 3.67 Million USD | 71.865% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | 0.0% |
| Evolus, Inc. | 126.54 Million USD | 99.184% |
| HUTCHMED (China) Limited | 86.13 Million USD | 98.801% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 99.834% |
| Akanda Corp. | 3.99 Million USD | 74.164% |